Skip to NavigationSkip to content

MSD signs $117m deal with Samsung Bioepis over Janssen biosimilar

Published on 08/10/18 at 09:47am

American multinational MSD have won a $117 million contract allowing them to supply Samsung Bioepis’ Renflexis to the US Department of Veteran Affairs.

The deal between the multibillion dollar pharma firm MSD, and the Samsung Biologics and Biogen Idec joint-venture Samsung Bioepis, will see MSD supply Renflexis, a biosimilar of Janssen’s Remicade (Infliximab) to the US federal agency that provides healthcare services to military veterans.

The deal comes after a 2013 deal between MSD and Samsung Bioepis settled that Merck would be responsible for commercialising multiple biosimilar candidates, in particular partnered territories.

Meanwhile Samsung Bioepis is responsible for preclinical and clinical development, process development and manufacturing, clinical trials and regulatory registration.

The biosimilar of the blockbuster monoclonal antibody which is used to treat autoimmune diseases such as Crohn’s disease, ulcerative colitis, psoriasis and rheumatoid arthritis gained FDA approval in April 2017.

Louis Goss


I am agree with the all information shared by you here and with the hlp of this add icons desktop in windows 10 which was so important for my desktop computer. Thank you to this informational web page.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches